arrow
O

Ouathek Ouerfelli

Memorial Sloan Kettering Cancer Center
H指数:41
被引数:7,045

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NSD2 targeting reverses plasticity and drug resistance in prostate cancer

NSD2靶向逆转前列腺癌的细胞可塑性和药物抵抗性

Nature
IF48.5
2025-11-260
OA
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression

Polycomb Repressor Complex 1通过协调干性维持和免疫抑制驱动双重阴性前列腺癌转移

2025-10-240
PRE
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177 Lu-Labeled Radiohapten
2024-08-210
PRE
Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness
2024-06-013
PRE
Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferase
2024-03-151
OAAI
APR-246 increases tumor antigenicity independent of p53
2023-10-273
OAAI
Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
2023-06-2211
OA
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
2021-06-04125
OA
Anti-tumor effects of an ID antagonist with no observed acquired resistance
2021-05-2413
OAAI
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
2021-02-2527
OA
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy

用于治疗性两步预靶向放射免疫疗法的自组装和分解 (SADA) 双特异性抗体 (BsAb) 平台

2021-01-1925
OAAI
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer
2020-11-1622
OAAI